Deregulation of signaling pathways involving phosphorylation is a hallmark of malignant transformation. Degradation of phosphoproteins generates cancer-specific phosphopeptides that are associated with MHC-I and II molecules and recognized by T-cells. We identified 95 phosphopeptides presented on the surface of primary hematological tumors and normal tissues, including 61 that were tumor-specific. Phosphopeptides were more prevalent on more aggressive and malignant samples. CD8 T-cell lines specific for these phosphopeptides recognized and killed both leukemia cell lines and HLA-matched primary leukemia cells ex vivo.
Introduction
Hematologic malignancies are susceptible to curative immunological therapies, such as stem cell transplantation, donor lymphocyte infusion and manipulation of endogenous immunity through immunostimulatory cytokines (1) (2) (3) (4) . The clinical utility of cellular immunotherapies provides powerful direct evidence that the adaptive immune response can control and eradicate tumors (5) (6) (7) (8) (9) . However, immunotherapies targeting identified tumor antigens have met with limited success, suggesting the optimal antigens remain undiscovered (10) (11) (12) . Moreover, the vast majority of identified tumor antigens are not derived from oncoproteins orchestrating the transformation process. Efforts targeting these antigens may be compromised by tolerance mechanisms and immune escape.
The importance of signal-transduction pathway deregulation in cancer pathogenesis is well-established (13) (14) (15) (16) (17) . Small molecule therapies targeting these pathways have met with considerable clinical success, providing a powerful argument for immunotherapies that target similar deregulated pathways (18) (19) (20) . Protein phosphorylation is the dominant mechanism involved in oncogenic signaling processes (21) . We previously showed that phosphorylation is preserved on peptides during antigen processing for presentation by both MHC-I and -II molecules (22) (23) (24) . This suggests that phosphopeptide antigens derived from cancer-related phosphoproteins could serve as immunological signatures of 'transformed self' (22) (23) (24) (25) (26) .
Moreover, phosphorylation can enhance the binding of peptides to MHC-I molecules, creating "neo-antigens". Collectively these results suggest that phosphopeptides are attractive targets for cancer immunotherapy (27) .
To date, no studies have examined MHC-I-bound phosphopeptides displayed on primary human tumor samples, nor has the human immune response against MHC-I restricted phosphopeptides been characterized. Here, we identify novel phosphopeptides from primary leukemia samples and show that healthy individuals display immune responses with memory characteristics against many of them. Immunity is lost in some patients with leukemia, but can be restored. This unexpected pre-existing immunity to phosphopeptides suggests that they could be targets of immune surveillance, and play a role in enabling immunological control of malignancies in humans.
Results

Characterization of Leukemia-Associated MHC Class-I Restricted Phosphopeptides
To identify tumor-associated phosphopeptides, we affinity-isolated HLA-A*0201 (HLA-A2) and HLA-B*0702 (HLA-B7) peptide complexes from 4 primary chronic lymphocytic leukemia (CLL) tumors, a primary hairy-cell leukemia (HCL), a primary mantle cell lymphoma (MCL), a primary acute lymphoblastic leukemia (ALL), and a primary acute myeloid leukemia (AML), in addition to normal splenic T and B-cells, bone marrow cells (BM), and cultured Blymphoblastoid cell lines (B-LCL). Collectively, 10 HLA-A2-restricted and 85 HLA-B7-restricted phosphopeptides were identified (Fig. 1a) . All tumor types and normal tissues expressed a greater number of HLA-B7 than HLA-A2 phosphopeptides (Fig. 1b) .
The large number of HLA-B7-restricted phosphopeptides enabled us to compare their representation on different tumor types and healthy tissue. On average more than twice as many were found on aggressive (AML and ALL) as on indolent (CLL and HCL) tumors or normal tissue (Fig. 1c) . Of 56 HLA-B7-restricted phosphopeptides identified on AML, 36 were not found on any other leukemia and only two were found on bone marrow (Figs. 1a, 2a) . Of 45 phosphopeptides identified on ALL, 19 were not found on other leukemias and 13/19 were also not observed on T-or B-cells (Fig. 2a) . Seven were derived from oncogenes implicated in leukemogenesis: MYC, EP300, SKI, GFI-1, Bcl-11A, MEF2D, and MLL (Fig. 1a) . Twentyseven HLA-B7 phosphopeptides were identified on two CLL tumors, all of which were shared with either AML or ALL. Sixteen were observed on normal tissue but seven were common to AML, ALL and CLL and not normal tissue (CCDC45, GRK2, SETD2, C17orf85, TSC22D4 and SPR(pS)PGKPM, derived from an unknown protein). These proteins have not been previously associated with leukemic malignancies and the functions of most remain undefined. Twenty-six of 27 CLL peptides were also found on HCL, which itself expressed one additional unique phosphopeptide. Twenty-four of these were also shared by B-LCL (Fig. 2b) . These results identify a cohort of phosphopeptides expressed on multiple leukemic malignancies, but not normal tissue, which represent potential immunotherapeutic targets.
Characteristics of the HLA-A2 bound phosphopeptides were similar to those previously reported (22, 23) . Of 85 HLA-B7-restricted phosphopeptides, two were dually phosphorylated and the remainder monophosphorylated, with 77/85 containing phosphoserine and 9/85 containing phosphothreonine. The phosphate was found at position four in 72% of HLA-B7 phosphopeptides, similar to the distribution in HLA-A2 phosphopeptides (Fig. S1a,b) (27) .
When compared with 1038 non-phosphorylated HLA-B7-restricted 9mer peptides in the ImmuneEpitope database (28), HLA-B7-restricted phosphopeptides showed a similar strong preference for proline at P2 and common hydrophobic C-terminal anchor residues (Fig. 2c, d ).
However, they showed an unusual bias for basic residues at P1 and proline at P5 (Fig 2c, Fig.   S1c ). To test whether these biases were imposed by an underlying kinase recognition motif, potential HLA-B7 binding 9mer peptides were identified in the Phosphosite dataset (29) of known serine phosphorylation sites. The position of the phosphoserine within 1031 phosphopeptides predicted to bind to HLA-B7 was not skewed towards P4 (Fig. 2e) . Thus, these biases likely reflect roles in binding to HLA-B7 analogous to those demonstrated for HLA-A2-associated phosphopeptides (27) . Of 164 predicted HLA-B7 binding peptides that had phosphoserine at P4 there was no apparent bias for basic residues at P1 (Fig. 2f) . However 87% contained a proline at P5 suggesting this bias reflects an underlying kinase motif, rather than being imposed by HLA binding.
Phosphopeptide-specific T-cell responses in healthy donors
Three HLA-A2 and two HLA-B7 phosphopeptides were derived from LSP-1, a lymphoma marker (30) . One, RQA(pS)IELPSMAV, is present on all HLA-A2 + tumor samples at high copy number. RQA(pS)IELPSMAV-pulsed dendritic cells were used to prime autologous T-cells.
Responses to this phosphopeptide could be elicited in 3/3 healthy individuals. Specific T-cells were enriched using HLA-A2-RQA(pS)IELPSMAV tetramers to produce T-cell lines (Fig. 3a) .
These lines secreted IFNγ in response to stimulators pulsed with RQA(pS)IELPSMAV, but not with unphosphorylated RQASIELPSMAV, nor to other phosphopeptides, including the closely related RQA(pS)IELPSM (Fig. 3b) . Recognition was therefore both phosphate-dependent and peptide sequence-specific. These lines also killed the HLA-A2 + AML cell line THP-1 and the HLA-A2 transfected ALL cell line, Jurkat-A2, but not untransfected Jurkat ( Fig. 3c-d) . Most importantly, RQA(pS)IELPSMAV-specific T-cells killed HLA-A2 + primary AML and CLL tumors, but not an HLA-A2 neg CLL tumor (Fig. 3e) . T-cell lines were also elicited against an HLA-B7 restricted phosphopeptide (RPT(pS)RLNRL) derived from NCOA-1 and showed remarkable phosphopeptide-specific killing of three primary CLL tumors (Fig. 3f) .
We next evaluated immunity in 10 healthy donors against 10 HLA-A2 and 76 HLA-B7 leukemia-associated phosphopeptides (Fig. 4a) recognized by most healthy donors, T-cell specificity was confirmed in 14-day cultures using HLA-phosphopeptide multimers (Fig. 4b) . Furthermore, these T-cells did not recognize the unphosphorylated counterpart peptides (Fig. 4c, Fig. S2 ). Collectively, these data demonstrate that the majority of leukemia-associated phosphopeptides elicited surprisingly strong and specific responses in a significant fraction of healthy individuals.
Leukemia-associated phosphopeptide-specific immunity in healthy donors. (Fig. 4e, Fig. S3 ). This suggests that the majority of healthy individuals have been previously exposed to a stimulus that establishes immunological memory to tumorassociated phosphopeptides.
Absent phosphopeptide-specific immunity in leukemia patients.
We next evaluated the level of phosphopeptide-specific CD8 T-cell immunity in immunocompetent patients with early-stage CLL ( Table S1 ). As tumor cells are present at high levels in PBMC from CLL patients, comparison with responses in PBMC from healthy individuals is problematic. Therefore, responses against a group of 12 CLL-associated phosphopeptides (identified by red dots in Fig. 1) were assessed by direct ex vivo ELISpot of purified CD8 T-cells (Fig. S4) . As expected, we detected immune responses to most of these phosphopeptides in all 10 healthy HLA-B7 + individuals (Fig. 5a ). However, 9/14 CLL patients (Group 1) had low or absent immunity to all 12 phosphopeptides (less than a combined total of breadth of recognition of different phosphopeptides similar to that of the healthy donors.
However, average responses to all phosphopeptides were significantly lower in Group 2 patients than in healthy individuals (Fig 5b) .
This lack of phosphopeptide-specific immunity in CLL patients might have been due to an overall depression of T-cell immunity. However, bulk CD8 T-cell responses to low level anti-CD3 were comparable in Group 1 and 2 patients and healthy donors (Fig. 5c ). To assess whether the lack of phosphopeptide-specific immunity in Group 1 patients reflected T-cell anergy, we analyzed patient responses to the pNCOA-1 phosphopeptide, which is immunogenic in 9/10 healthy donors, in the presence of IL-2 as this cytokine has been shown to reverse the anergic state (32) . Responses to anti-CD3 increased in the presence of IL-2, but no antiphosphopeptide immunity was detected (Fig. S5 ). This suggests that pre-existing phosphopeptide immune T-cells in Group 1 patients had been deleted, or had never developed, rather than being anergized.
Although CLL is a less aggressive tumor than either AML or ALL, the disease is more aggressive in a subgroup of patients. Thus, we assessed whether the level of phosphopeptidespecific immunity was associated with patient outcome. Despite selecting patients with early stage disease, there were large differences in progression-free survival, overall survival and time to first treatment between Group 1 and Group 2. Group 2 patients survived longer and required less treatment than Group 1 patients (Figs. 5d-f). However, due to the small study size these differences did not reach statistical significance.
We extended these studies to a cohort of 12 HLA-B7 + AML patients in complete remission (Table S2 ) using a panel of 12 AML-specific phosphopeptides (green dots in Fig. 1 ).
Responses to most of these phosphopeptides were detected in 12 healthy donors after 7-day in vitro culture ( Fig. 6a, Fig. S6 ). However, as with CLL patients, the average responses of AML patients to individual phosphopeptides were significantly lower (Fig 6b, P<0 .0001). AML patients could also be stratified: Group 1 patients (10/12) showed a profound lack of phosphopeptide-specific immunity, while Group 2 (2/12) showed responses that were similar to those of normal donors. Again, responses to low dose anti-CD3 were similar between the groups, indicating that the lack pre-existing anti-phosphopeptide responses in patients is not due to immune incompetence (Fig. S6 ). In keeping with this, absolute lymphocyte counts for all 12 AML patients were within the normal range pre-transplant (Table S2) . Collectively, these findings demonstrate that the majority of patients with either CLL or AML have reduced preexisting immunity specific for leukemia-associated phosphopeptides.
Restoration of phosphopeptide-specific immunity after stem cell transplantation (SCT).
A graft versus leukemia (GvL) response following allogeneic SCT correlates with a positive clinical outcome in AML patients. While it is believed that GvL is directed to minor histocompatibility antigens (mHAgs), the targets have been only partly identified (32) . We hypothesised that SCT might also reconstitute potentially protective immunity against leukemiaassociated phosphopeptides in AML patients. All 12 AML patients went on to have allogeneic SCT. Immunity against the 12 AML-specific phosphopeptides was at least partly restored in the majority of patients studied (Fig. 6c, Fig. S5 ). Marked expansion of immune responses to six different phosphopeptides was observed in patient AML2 (Fig. 6d) , while patient AML4 showed dramatic expansion of responses to MLL(EPR) and LSP1(QPR) phosphopeptides, and modestly increased responses to C17orf85 and SKI (Fig 6e) . Some of these responses were as large as those against an immunodominant CMV epitope (pp65) and the resulting T-cells bound HLAphosphopeptide tetramers. Furthermore, in vitro expanded MLL(EPR)-specific T-cells from patient AML4 killed AML cells (Fig. 6f) confirming their functional relevance. These data reveal a linkage between immunity to leukemia-associated phosphopeptides and GvL following allogeneic SCT
Discussion
Posttranslationally modified antigens are increasingly being shown to play important roles in human disease (33) (34) (35) (36) (37) ). Here we have tested the hypothesis that phosphopeptide neoantigens could be identified on primary human malignant tissue and would be immunogenic in healthy donors or patients with cancer. We now report 95 phosphopeptides displayed on the surface of primary hematological malignant tissue in association with two dominant human MHC-I molecules. We observed substantial differences in the number of phosphopeptides presented by different HLA alleles, although the underlying mechanism for these differences is unclear. Our results establish that MHC-I displayed phosphopeptides are over-represented on multiple leukemic malignancies, and that more aggressive malignancies display a greater diversity of them. Many of these tumor-associated phosphopeptides are derived from oncogenes linked to leukemogenesis, making these of particular interest as immunotherapeutic targets.
Unexpectedly, many of these phosphopeptides were the targets of pre-existing immunity, based on high levels of responding CD8 T-cells with a predominantly central memory phenotype. The levels of responding cells were similar to those directed against immunodominant epitopes from some non-persistent viruses. These T-cells, when expanded in vitro, bound to HLA-B7-phosphopeptide tetramers, and recognized and killed primary tumor cells, suggests they were high avidity. These observations contrast with those reported for other tumor-associated antigens. Immunity to cancer-testis antigens is generally not present in healthy individuals, and becomes detectable in patients with cancer, but is associated with a poor prognosis (38, 39) . Immunity to tissue-associated differentiation antigens, particularly those defined as targets for melanoma-specific T-cells, is also elevated in melanoma patients (40, 41) , but is believed to be compromised by self-tolerance (42, 43) . Importantly, none of the healthy donors in which these memory-compartment associated immune responses were evident showed any signs of autoimmune disease. This suggests that these phosphopeptides are displayed on normal tissue at levels that are substantially lower than those on tumors. In keeping with this, Tcells specific for LSP1 (RQAV) and NCOA-1 recognize tumors, but not resting B-cells, despite the presence of these epitopes on the latter cells.
Although a small study, these findings suggest that the majority of healthy individuals have been previously exposed to a stimulus that establishes immunological memory to substantial numbers of phosphopeptides. For a small number of these phosphopeptides, immunological memory is prevalent among most individuals examined. The mechanism that underlies the development of phosphopeptide-specific memory CD8 T-cells is of great interest.
While it is possible that a distinct, cross-reactive stimulus could be responsible for the development of a generic phosphate-directed immunity, all of the T-cells studied to date are specific for the phosphate, the specific peptide sequence, and the MHC molecule that presents it.
On the other hand, hematolymphoid transformation by Epstein-Barr virus (EBV) is ubiquitous in In this present study we have been unable to demonstrate a direct causal relationship between the lack of cellular immunity against phosphorylated antigens in patients, with disease development and/or progression. Neither have we been able to connect, at the molecular level, deregulated oncogenic signaling present in each primary tumor, to the phosphorylation events present within the defined antigens. Larger, more complex and extensive studies, will be needed to define these relationships. Collectively, however, our results suggest that the display of MHC-associated phosphopeptides may play a role in preventing either the development or progression of malignant disease. Thus, enhancing immunity to these tumor-associated antigens should become a focus of future cancer immunotherapeutic strategies.
Materials and Methods
Tumor samples and cell lines. Blood or leukapheresis samples were taken from patients with high-burden leukemia in heparin, and tumor cells were isolated on Ficoll density gradients. The purity of the tumor was >98% pure in all cases as assessed by flow cytometry. Healthy T and Bcell populations were isolated from normal spleen and tonsil samples processed by mechanical disruption, followed by density gradient separation and enrichment using anti-CD19 or anti-CD3 microbeads (Miltenyi Biotec) to >98% purity. Bone marrow sample was obtained from an elective orthopedic procedure and red cell depleted using hypotonic lysis. All cell lines were grown at 37°C with 5% CO 2 in medium consisting of RPMI-1640 supplemented with 10% Fetal Bovine Serum (FBS) and 2 mM L-glutamine (all from Sigma-Aldrich).
Isolation of HLA-associated peptides. Class-I MHC molecules were immunoaffinity purified from samples, and their associated peptides were extracted, as described (22) Sequence analysis of HLA-Associated Phosphopeptides. Immunoaffinity-purified class I peptides were converted to d 0 -or d 3 -methyl esters and subjected to Fe +3 -immobilized metalaffinity chromatography to isolate phosphopeptides, as described (22) . Phosphopeptide methyl esters were then analyzed by a combination of nanoflow HPLC, microelectrospray ionization, and collision activated dissociation on LTQ/FT or Orbitrap tandem mass spectrometers (Thermo Scientific) (22) . Electron transfer dissociation (ETD) spectra were acquired on an in-house modified LTQ mass spectrometer (56) . Peptide sequences were determined by manual interpretation of CAD and ETD spectra recorded on the above peptide esters. If necessary, phosphopeptide sequences were confirmed by recording tandem mass spectra on the corresponding synthetics.
Epitope Prediction. This was performed using SYFPEITHI and a threshold score of 20.
Peptides. Peptides used in this study were synthesized with Fmoc chemistry, isolated by HPLC to >90% purity, and validated with mass spectrometry (EZ-Biolabs and Genscript).
HLA-phosphopeptide Tetramers. HLA tetramers were produced as described (57) .
Generation of Human Phosphopeptide-Specific CD8 Cytotoxic T-cell lines. HLA-A2
restricted RQA(pS)IELPSMAV phosphopeptide-specific cytotoxic CD8 T-cells were generated from healthy donors as described previously (58). All cytokines were from PeproTech except where stated. Briefly, PBMCs were cultured in flat-bottom 6-well plates at 10 7 cells per well in RPMI-1640 plus 10% heat-inactivated human AB serum (Biosera) (10% media). GM-CSF (800 IU/ml) and IL-4 (1000U/mL) were added on day 0 to generate dendritic cells (DC). On day 1, a maturation cocktail containing 100ng/ml TNF, 100ng/ml IL-1β, 10,000IU/ml IL-6, 8000 IU/ml GM-CSF and 10 µg/ml PGE 2 (Sigma-Aldrich) was added. On day 2, DCs were harvested and loaded with phosphopeptide (20µg/ml) for 4 hours in the absence of FBS or human serum.
Following three washes, T-cells were added at a ratio of five T-cells per DC in 10% media.
Recombinant IL-7 (10ng/ml) and IL-15 (10ng/ml) were added on day 5. On day 9, T-cells were harvested and re-stimulated by adding 10 7 irradiated PBMCs and 10 6 irradiated autologous LCLs pulsed with phosphopeptide with IL-7 (5ng/ml), IL-15 (5ng/ml) and IL-2 (20IU/ml). Cultures were re-stimulated every 7 days thereafter in the same manner. At each re-stimulation T-cells were enriched using either anti-CD8 microbeads (Miltenyi Biotec) or by labeling with HLAphosphopeptide tetramers and using anti-PE microbeads (Miltenyi Biotec).
HLA-B7 restricted anti-phosphopeptide T-cells were grown in the absence of dendritic cells by plating 5x10 6 PBMCs in 48 well plates in 10% media with individual phosphopeptides at 10µg/ml for 7 days without cytokines. Re-stimulations with irradiated phosphopeptide-pulsed autologous PBMCs took place every 7 days with cytokines added 3 days after each restimulation (final concentration 20IU/ml IL-2, 5ng/ml IL-7 and 5ng/ml IL-15). Functional and cytotoxicity assays were then performed from day 13.
T-cell recognition assays. For ELISpot analysis, PBMCs or CD8 T-cells were isolated fresh
from in heparinized blood taken from healthy donors and patients. 1x10 6 PBMCs were isolated from both AML patients and healthy donors and re-suspended in AIM-V media (Invitrogen) with 10% human AB serum (Biosera) in a 96 well plate. For 7-day assays peptide or phosphopeptides were added individually at 10g/ml and placed at 37°C in CO 2 incubator for 7 days. For CLL patients a different approach had to be taken as PBMCs contain largely tumor cells. Therefore CD8 T-cells were magnetically enriched using anti-CD8 microbeads (Miltenyi Biotec) to a purity of >99% for both healthy donors and patients with CLL. 200,000 CD8 T-cells from both patients and healthy donors were used for ELISpot analysis as described above.
Cytotoxicity assays. Cytotoxic activity was evaluated in a standard 4 hour 51
Cr release assay, as previously described (57) .
Statistical Analysis
We analyzed the data using the Kaplan-Meier for the survival rate, the unpaired t-test for twogroup comparisons. We performed the statistical analyses using Prism version 5 (GraphPad). P values <0.05 were considered significant. Table S1 . CLL patient characteristics. P1  P2  P3  P4  P5  P6  P7  P8  P9  P1  P2  P3  P4  P5  P6  P7  P8  P9   P1  P2  P3  P4  P5  P6  P7  P8  P9 HLA-B7 phosphopeptide ligands (X=pSer)
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